Biapenem is a 1β-methyl carbapenem antibiotic for injection developed by Lederle Corporation of Japan and Cyanamide Company of the United States. It was approved for marketing in Japan in March 2002 and is currently undergoing Phase II clinical trials in the United States. test. This product, like melopenem, has a broad antibacterial spectrum and strong antibacterial activity.
Biapene has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria (including resistant Pseudomonas aeruginosa), anaerobic bacteria, etc.; stable to b-lactamase; stable to DHP-1 Sex is stronger than imipenem. Compared with other listed carbapenems, it has almost zero nephrotoxicity and can be administered alone; it has no central nervous system toxicity, can not induce seizures, and can be used for the treatment of bacterial meningitis.
This product is 2 to 4 times stronger than Pseudomonas aeruginosa and anaerobic bacteria, and inhibits drug-resistant Pseudomonas aeruginosa 4 to 8 times stronger than meropenem. It is effective against Acinetobacter and anaerobic bacteria than ceftazidime.